[Bone diseases with Pain. Osteoporosis].
Approximately 85 % of the patients with osteoporosis are suffered from bone pain. And almost 100 % of the patients eagerly ask the physician to relieve their pain. But many physicians concerning treatment of osteoporosis had been interested in increase of bone mineral density, decrease of fracture rate and improvement of bone quality, instead of relief of the pain. A reason of indifference of medical doctor for pain relief would be based on uncertain pathogenesis of bone pain, such as many spinal fractures occurred without pain in the huge study of clinical efficacy of a bisphosphonate. Recently, a detailed study focused on spinal pain revealed that 90% of spinal fracture were accompanied the pain. On the other hand, many bisphosphonates in addition to calcitonin were clarified to show analgesic effect. So many medical doctors have been interested in relief of osteoporotic pain. The purpose of treatment of osteoporosis in 21st century would again become relief of the pain, based on the reduction of fracture rate.
Hayashi
Yasufumi
Y
Tokyo Metropolitan Rehabilitation Hospital, Department of Orthopaedics.
D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002116:Calcitonin / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use*; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000150:complications* / Q000188:drug therapy* / Q000517:prevention & control; D010146:Pain / Q000188:drug therapy* / Q000209:etiology*; D011788:Quality of Life; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D002116:Calcitonin; D002118:Calcium